ONCOLOGY LETTERS 10: 1204-1210, 2015
1204
Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer BYEONG SEOK SOHN1, YOUNG JIN YUH1, HONG SUK SONG2, BONG‑SEOG KIM3, KYUNG HEE LEE4, JOUNG‑SOON JANG5 and SUNG ROK KIM1 1
Department of Internal Medicine, College of Medicine, Inje University Sanggye Paik Hospital, Seoul 139‑707; Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu 700‑712; 3 Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 139‑707; 4Division of Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 702‑701; 5 Division of Hematology/Oncology, Department of Internal Medicine, Chung‑Ang University College of Medicine, Seoul 139‑707, Republic of Korea
2
Received September 4, 2014; Accepted May 20, 2015 DOI: 10.3892/ol.2015.3347 Abstract. In advanced or relapsed pancreatic cancer, mono- or duo-therapy has shown modest efficacy at best. The present study evaluated the efficacy of a triplet combination in relapsed or advanced pancreatic cancer. A total of 37 patients with adenocarcinoma of the pancreas in stage III/IV or with relapsed disease were treated with a gemcitabine, 5‑fluorouracil and cisplatin (GFP) regimen every 3 weeks. Only 29 out of 37 patients were evaluable for response due to early treatment interruption in 8 patients. The overall response rate was 24.1% and the disease control rate was 68.9%. The progression‑free survival (PFS) rate was 61.5, 30.9 and 17.6% at 3, 6 and 9 months, respectively, and the overall survival (OS) rate was 46.5 and 30.6% at 6 and 12 months, respectively. Grade 3/4 leukopenia, neutropenia and thrombocytopenia occurred in 18.4, 29.9 and 24.5% of 147 cycles, respectively. Old age and a poor performance status (PS) were associated with the early discontinuation of chemotherapy (P=0.038 and P= 0.036, respectively). In patients
1204
Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer BYEONG SEOK SOHN1, YOUNG JIN YUH1, HONG SUK SONG2, BONG‑SEOG KIM3, KYUNG HEE LEE4, JOUNG‑SOON JANG5 and SUNG ROK KIM1 1
Department of Internal Medicine, College of Medicine, Inje University Sanggye Paik Hospital, Seoul 139‑707; Department of Hematooncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu 700‑712; 3 Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 139‑707; 4Division of Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 702‑701; 5 Division of Hematology/Oncology, Department of Internal Medicine, Chung‑Ang University College of Medicine, Seoul 139‑707, Republic of Korea
2
Received September 4, 2014; Accepted May 20, 2015 DOI: 10.3892/ol.2015.3347 Abstract. In advanced or relapsed pancreatic cancer, mono- or duo-therapy has shown modest efficacy at best. The present study evaluated the efficacy of a triplet combination in relapsed or advanced pancreatic cancer. A total of 37 patients with adenocarcinoma of the pancreas in stage III/IV or with relapsed disease were treated with a gemcitabine, 5‑fluorouracil and cisplatin (GFP) regimen every 3 weeks. Only 29 out of 37 patients were evaluable for response due to early treatment interruption in 8 patients. The overall response rate was 24.1% and the disease control rate was 68.9%. The progression‑free survival (PFS) rate was 61.5, 30.9 and 17.6% at 3, 6 and 9 months, respectively, and the overall survival (OS) rate was 46.5 and 30.6% at 6 and 12 months, respectively. Grade 3/4 leukopenia, neutropenia and thrombocytopenia occurred in 18.4, 29.9 and 24.5% of 147 cycles, respectively. Old age and a poor performance status (PS) were associated with the early discontinuation of chemotherapy (P=0.038 and P= 0.036, respectively). In patients
